Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03184038 · ClinicalTrials.gov registry record · NA

Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

A NA study of Metastatic Malignant Solid Neoplasm and Metastatic Malignant Neoplasm in the Brain, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

Recruiting
Registry status
NA
Development phase
90
Enrollment target
2
Study locations

NCT03184038 is a NA study of Metastatic Malignant Solid Neoplasm and Metastatic Malignant Neoplasm in the Brain that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 90 participants, below the 205-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (56% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03184038, a NA study of Metastatic Malignant Solid Neoplasm and Metastatic Malignant Neoplasm in the Brain, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

RECRUITING
Registry status
NA
Development phase
90 participants
Enrollment target
2
Study locations

Study Summary

This phase II trial studies the neurological function in patients with multiple brain metastases undergoing stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT). Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Assessment of neurocognitive function may help show that SRS preserves neurological function in patients with multiple brain metastases better than SBRT.

Interventions

  • OTHER Quality-of-Life Assessment
  • RADIATION Stereotactic Body Radiation Therapy
  • RADIATION Stereotactic Radiosurgery
  • PROCEDURE Cognitive Assessment

Study Locations (2)

New Jersey

  • Jefferson Health New Jersey - Sewell

Pennsylvania

  • Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2017-02-21
Est. Completion 2026-09-30
Phase NA

What the Registry Record Tells You About NCT03184038

The ClinicalTrials.gov registry entry for NCT03184038 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (56% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Malignant Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.

NCT03184038 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03184038 about?

NCT03184038 is a clinical study titled "Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery". This phase II trial studies the neurological function in patients with multiple brain metastases undergoing stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT). Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors ...

What is the current status of trial NCT03184038?

This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2017-02-21. Estimated completion is 2026-09-30.

What conditions does trial NCT03184038 study?

This clinical trial studies the following conditions: Metastatic Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain.

What interventions are being tested in trial NCT03184038?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Stereotactic Body Radiation Therapy (RADIATION), Stereotactic Radiosurgery (RADIATION), Cognitive Assessment (PROCEDURE).

Who is sponsoring clinical trial NCT03184038?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03184038 being conducted?

This trial has 2 study locations across New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.